{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:52:59Z","timestamp":1776228779780,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.leukres.2026.108203","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:11:40Z","timestamp":1774051900000},"page":"108203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-6212","authenticated-orcid":false,"given":"Lachelle","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata S.","family":"Chandhok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2026.108203_bib1","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","article-title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes","volume":"11","author":"Komrokji","year":"2024","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108203_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108203_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2026.108203_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000658","article-title":"Novel approaches and future directions in myelodysplastic syndrome treatment","volume":"29","author":"Bewersdorf","year":"2023","journal-title":"Cancer J."},{"issue":"9","key":"10.1016\/j.leukres.2026.108203_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.leukres.2026.108203_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.leukres.2026.108203_bib7","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2026.108203_bib8","unstructured":"FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia | FDA. Accessed April 27, 2025. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell\u3009."},{"key":"10.1016\/j.leukres.2026.108203_bib9","unstructured":"FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia | FDA. Accessed April 27, 2025. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute\u3009."},{"key":"10.1016\/j.leukres.2026.108203_bib10","unstructured":"Drugs Approved for Leukemia - NCI. Accessed April 27, 2025. \u3008https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/leukemia\u3009."},{"issue":"4","key":"10.1016\/j.leukres.2026.108203_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11899-013-0172-3","article-title":"There\u2019s risk, and then there\u2019s risk: the latest clinical prognostic risk stratification models in myelodysplastic syndromes","volume":"8","author":"Zeidan","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2026.108203_bib12","article-title":"Approaching a therapeutic inflection point for FLT3-mutated AML","author":"Perl","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44228-022-00024-4","article-title":"How I manage transplant ineligible patients with myelodysplastic neoplasms","volume":"5","author":"Gurnari","year":"2022","journal-title":"Clin. Hematol. Int"},{"issue":"17","key":"10.1016\/j.leukres.2026.108203_bib14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.leukres.2026.108203_bib15","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv."},{"issue":"13","key":"10.1016\/j.leukres.2026.108203_bib16","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","author":"Issa","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2026.108203_bib18","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.22.02721","article-title":"Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML","volume":"41","author":"Pratz","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108203_bib19","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108203_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2026.108203_bib21","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2026.108203_bib22","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108203_bib23","unstructured":"VYXEOS\u00ae | A Treatment for sAML. Accessed December 1, 2025. \u3008https:\/\/www.vyxeospro.com\/\u3009."},{"key":"10.1016\/j.leukres.2026.108203_bib24","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Acute Myeloid Leukemia. National Comprehensive Cancer Network. 2024;Version 1.2025. ."},{"issue":"4","key":"10.1016\/j.leukres.2026.108203_bib25","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clml.2021.09.019","article-title":"Secondary acute myeloid leukemia (sAML): similarly dismal outcomes of AML after an antecedent hematologic disorder and therapy related AML","volume":"22","author":"Lalayanni","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2026.108203_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36255\/exon-publications-leukemia-secondary-acute-myeloid-leukemia","article-title":"Secondary acute myeloid leukemia: pathogenesis and treatment","author":"Capelli","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2026.108203_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108203_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2026.108203_bib29","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108203_bib30","doi-asserted-by":"crossref","unstructured":"Fathi A., Perl A., Fell G., et al. Results from paradigm-a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. In: 67th ASH\u00ae Annual Meeting. 2025:Publication Number: 6.","DOI":"10.1182\/blood-2025-6"},{"issue":"16","key":"10.1016\/j.leukres.2026.108203_bib31","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.3390\/ijms25169023","article-title":"KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives","volume":"25","author":"Guarnera","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"7954","key":"10.1016\/j.leukres.2026.108203_bib32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to Menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.leukres.2026.108203_bib33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"issue":"7954","key":"10.1016\/j.leukres.2026.108203_bib34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/cancers12010201","article-title":"Characterization of the Menin-MLL interaction as therapeutic cancer target","volume":"12","author":"Brzezinka","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"16_","key":"10.1016\/j.leukres.2026.108203_bib36","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/JCO.2025.43.16_suppl.6506","article-title":"Ziftomenib in relapsed\/refractory (R\/R) NPM1-mutant acute myeloid leukemia (AML): phase 1b\/2 clinical activity and safety results from the pivotal KOMET-001 study","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108203_bib37","doi-asserted-by":"crossref","unstructured":"Aldoss I., Issa G., Blachly J., et al. Revumenib for patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101. In: 67th ASH\u00ae Annual Meeting. 2025:Publication Number: 1001.","DOI":"10.1182\/blood-2025-1001"},{"key":"10.1016\/j.leukres.2026.108203_bib38","doi-asserted-by":"crossref","unstructured":"Roboz G., Wang E., Fathi A., et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007. In: 67th ASH\u00ae Annual Meeting. 2025:Publication Number: 766.","DOI":"10.1182\/blood-2025-766"},{"key":"10.1016\/j.leukres.2026.108203_bib39","unstructured":"Zeidner J. Phase 1 Results: First-in-Human Phase 1\/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia. ASH. Preprint posted online December 7, 2024."},{"issue":"23","key":"10.1016\/j.leukres.2026.108203_bib40","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108203_bib41","series-title":"European Hematology Association 2024","article-title":"A phase 1b study of the menin-KMT2A inhibitor bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine in relapsed\/refractory acute myeloid leukemia with alterations in KMT2A or NPM1","author":"Wei","year":"2024"},{"key":"10.1016\/j.leukres.2026.108203_bib42","unstructured":"Astellas. XOSPATA (Gilteritinib) [Prescribing Information].; 2022. \u3008www.fda.gov\/medwatch\u3009."},{"issue":"18","key":"10.1016\/j.leukres.2026.108203_bib43","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2026.108203_bib44","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2026.108203_bib45","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2026.108203_bib46","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","article-title":"Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","volume":"37","author":"Zeidan","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/hematology.2024000557","article-title":"Nontransplant treatment approaches for myeloid neoplasm with mutated TP53","volume":"2024","author":"Mehta","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"10.1016\/j.leukres.2026.108203_bib49","article-title":"Myeloid neoplasms with germline predisposition: practical considerations and complications in the search for new susceptibility loci","volume":"33","author":"Carraway","year":"2020","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"22","key":"10.1016\/j.leukres.2026.108203_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225690","article-title":"The impact of clonal hierarchy and heterogeneity on phenotypic manifestations of myelodysplastic neoplasms","volume":"14","author":"El Hussein","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.leukres.2026.108203_bib51","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"issue":"22","key":"10.1016\/j.leukres.2026.108203_bib52","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/hematology.2024000558","article-title":"Transplant options and outcomes for TP53 myeloid disease","volume":"2024","author":"Fern\u00e1ndez","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01571-4","article-title":"A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC","volume":"17","author":"Xiao","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108203_bib55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/2643-3230.BCD-25-0047","article-title":"Multimodal and data-driven assessment of myeloid neoplasms refines classification across disease states","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"21","key":"10.1016\/j.leukres.2026.108203_bib56","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"25","key":"10.1016\/j.leukres.2026.108203_bib57","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108203_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2026.108203_bib59","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108203_bib60","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","article-title":"How I treat MDS after hypomethylating agent failure","volume":"133","author":"Santini","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108203_bib61","first-page":"339","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"Kr\u00f6ger","year":"2024","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.leukres.2026.108203_bib62","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108203_bib63","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.leukres.2026.108203_bib64","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2026.108203_bib65","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.3390\/ijms21103432","article-title":"TP53 in myelodysplastic syndromes: recent biological and clinical findings","volume":"21","author":"Cumbo","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"28","key":"10.1016\/j.leukres.2026.108203_bib66","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study","volume":"41","author":"Versluis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108203_bib67","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3324\/haematol.2017.181180","article-title":"Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome \u2013 not because we can, but because we should","volume":"102","author":"Cutler","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108203_bib68","unstructured":"VERONA phase 3 trial shows no survival benefit in high-risk MDS - SOHO Insider. Accessed December 2, 2025. \u3008https:\/\/sohoinsider.com\/news\/verona-phase-3-trial-shows-no-survival-benefit-in-high-risk-mds\/\u3009."},{"key":"10.1016\/j.leukres.2026.108203_bib69","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G., Platzbecker U., Fenaux P., et al. Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-na\u00efve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS). In: 67th ASH\u00ae Annual Meeting. Publication Number: 235.","DOI":"10.1182\/blood-2025-235"},{"issue":"10399","key":"10.1016\/j.leukres.2026.108203_bib70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2026.108203_bib71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"6465","key":"10.1016\/j.leukres.2026.108203_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.leukres.2026.108203_bib73","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts","volume":"9","author":"Short","year":"2025","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.leukres.2026.108203_bib74","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult philadelphia chromosome-positive ALL: a GRAAPH-2014 Study","volume":"42","author":"Kim","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.leukres.2026.108203_bib75","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.leukres.2026.108203_bib76","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-11-1227","article-title":"CDKN2A\/B alterations impair prognosis in adult BCR-ABL1\u2013positive acute lymphoblastic leukemia patients","volume":"17","author":"Iacobucci","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2026.108203_bib77","article-title":"Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia","volume":"12","author":"Song","year":"2022","journal-title":"Front Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108203_bib78","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib79","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108203_bib80","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.leukres.2026.108203_bib81","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108203_bib82","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.26634","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108203_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib85","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01709-y","article-title":"Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108203_bib86","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.056135","article-title":"IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol","volume":"98","author":"D\u00f6rge","year":"2013","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.leukres.2026.108203_bib87","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"Van Der Veer","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108203_bib88","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/leu.2015.199","article-title":"Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study","volume":"30","author":"Boer","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2026.108203_bib89","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2026.108203_bib90","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2026.108203_bib91","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2026.108203_bib92","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2026.108203_bib93","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2021011822","article-title":"Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab","volume":"138","author":"Puzzolo","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2026.108203_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70161","article-title":"The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"13","author":"Wu","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.leukres.2026.108203_bib95","doi-asserted-by":"crossref","unstructured":"Goulart H., Jabbour E., Jain N., et al. Blinatumomab and Ponatinib Demonstrates Ongoing Efficacy as Frontline Therapy in Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 2 Study.; 2025.","DOI":"10.1182\/blood-2025-1571"},{"issue":"24","key":"10.1016\/j.leukres.2026.108203_bib96","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2026.108203_bib97","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph\u2013 B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108203_bib98","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","author":"Gupta","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.leukres.2026.108203_bib99","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International workshop for myelodysplastic syndromes","volume":"36","author":"Zeidan","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2026.108203_bib100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.leukres.2026.108203_bib101","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2026.108203_bib102","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2026.108203_bib103","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med"},{"issue":"21","key":"10.1016\/j.leukres.2026.108203_bib104","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.leukres.2026.108203_bib105","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:00:24Z","timestamp":1776225624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":105,"alternative-id":["S0145212626000470"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108203","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108203"}}